Spero Therapeutics, Inc. (SPRO): Price and Financial Metrics
GET POWR RATINGS... FREE!
SPRO POWR Grades
- Value is the dimension where SPRO ranks best; there it ranks ahead of 47.95% of US stocks.
- SPRO's strongest trending metric is Growth; it's been moving down over the last 179 days.
- SPRO's current lowest rank is in the Momentum metric (where it is better than 4.64% of US stocks).
SPRO Stock Summary
- Spero Therapeutics Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 14.29% of US listed stocks.
- For SPRO, its debt to operating expenses ratio is greater than that reported by merely 12.43% of US equities we're observing.
- With a price/sales ratio of 15.25, Spero Therapeutics Inc has a higher such ratio than 90.7% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to Spero Therapeutics Inc, a group of peers worth examining would be APM, PRTC, LOGC, LCTX, and BLDP.
- SPRO's SEC filings can be seen here. And to visit Spero Therapeutics Inc's official web site, go to sperotherapeutics.com.
SPRO Valuation Summary
- In comparison to the median Healthcare stock, SPRO's EV/EBIT ratio is 124.91% lower, now standing at -7.3.
- Over the past 47 months, SPRO's price/sales ratio has gone down 179.1.
- Over the past 47 months, SPRO's price/sales ratio has gone down 179.1.
Below are key valuation metrics over time for SPRO.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| SPRO | 2021-08-31 | 33.7 | 6.9 | -8.2 | -7.3 |
| SPRO | 2021-08-30 | 31.6 | 6.4 | -7.7 | -6.8 |
| SPRO | 2021-08-27 | 29.7 | 6.0 | -7.2 | -6.4 |
| SPRO | 2021-08-26 | 29.1 | 5.9 | -7.1 | -6.2 |
| SPRO | 2021-08-25 | 29.6 | 6.0 | -7.2 | -6.4 |
| SPRO | 2021-08-24 | 28.4 | 5.8 | -6.9 | -6.1 |
SPRO's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- SPRO has a Quality Grade of C, ranking ahead of 28.84% of graded US stocks.
- SPRO's asset turnover comes in at 0.128 -- ranking 241st of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows SPRO's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.128 | 1 | -1.651 |
| 2021-03-31 | 0.108 | 1 | -1.872 |
| 2020-12-31 | 0.072 | 1 | -2.390 |
| 2020-09-30 | 0.094 | 1 | -2.720 |
| 2020-06-30 | 0.110 | 1 | -2.104 |
| 2020-03-31 | 0.108 | 1 | -1.684 |
SPRO Price Target
For more insight on analysts targets of SPRO, see our SPRO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $38.17 | Average Broker Recommendation | 1.58 (Moderate Buy) |
SPRO Stock Price Chart Interactive Chart >
SPRO Price/Volume Stats
| Current price | $0.83 | 52-week high | $19.87 |
| Prev. close | $0.74 | 52-week low | $0.73 |
| Day low | $0.74 | Volume | 218,100 |
| Day high | $0.84 | Avg. volume | 470,242 |
| 50-day MA | $1.89 | Dividend yield | N/A |
| 200-day MA | $10.21 | Market Cap | 27.16M |
Spero Therapeutics, Inc. (SPRO) Company Bio
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. It is developing SPR994, an oral carbapenem-class antibiotic for use in adults to treat MDR gram-negative infections; SPR741 that has completed Phase I clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic that is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections. The company was founded in 2013 and is based in Cambridge, Massachusetts.
Latest SPRO News From Around the Web
Below are the latest news stories about Spero Therapeutics Inc that investors may wish to consider to help them evaluate SPRO as an investment opportunity.
Spero Therapeutics (SPRO) Gets a Buy Rating from Berenberg BankIn a report released today, Esther Hong from Berenberg Bank maintained a Buy rating on Spero Therapeutics (SPRO – Research Report), with a price target of $44.00. The company's shares closed last Wednesday at $9.35. According to TipRanks.com, Hong is ranked 0 out of 5 stars with an average return of -23.0% and a 20.8% success rate. Hong covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Aldeyra Therapeutics, and Aprea Therapeutics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Spero Therapeutics with a $44.00 average price target, representing a 331.8% upside. |
Spero Therapeutics antibiotic SPR206 shows promise in phase 1 trialSpero Therapeutics (SPRO) reported positive results from a phase 1 trial of its antibiotic SPR206 to treat serious multi-drug resistant ((MDR)) gram-negative infections in the… |
Spero Therapeutics Sees Positive Topline Results for Antibiotic TrialBy Chris Wack Spero Therapeutics Inc. said it saw positive topline findings from its Phase 1 bronchoalveolar lavage clinical trial of SPR206, an… |
Spero Therapeutics Announces Positive Topline Results from Phase 1 Bronchoalveolar Lavage Clinical Trial of SPR206, A Novel Intravenous Next Generation Polymyxin Antibiotic for the Treatment of Multi-drug Resistant Gram-Negative Infections in the Hospital SettingSPR206 shown to be well-tolerated; achieved lung exposures consistent with predicted therapeutic levels, when administered three times daily at 100 mg Results support further development of SPR206 in the setting of hospital-acquired pneumonia and ventilator-associated pneumonia CAMBRIDGE, Mass., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced topline findings from its Phase 1 bronchoalveolar lavage (BAL) clinical trial of SPR206, an intravenously (IV)-a |
The past year for Spero Therapeutics (NASDAQ:SPRO) investors has not been profitableIt's easy to match the overall market return by buying an index fund. Active investors aim to buy stocks that vastly... |
SPRO Price Returns
| 1-mo | -20.19% |
| 3-mo | -87.85% |
| 6-mo | -94.43% |
| 1-year | -94.74% |
| 3-year | -93.05% |
| 5-year | N/A |
| YTD | -94.82% |
| 2021 | -17.43% |
| 2020 | 101.66% |
| 2019 | 56.34% |
| 2018 | -47.66% |
| 2017 | N/A |
Continue Researching SPRO
Want to do more research on Spero Therapeutics Inc's stock and its price? Try the links below:Spero Therapeutics Inc (SPRO) Stock Price | Nasdaq
Spero Therapeutics Inc (SPRO) Stock Quote, History and News - Yahoo Finance
Spero Therapeutics Inc (SPRO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...